Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II dose (RP2D), and dose-limiting toxicities (DLTs...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Park, Haeseong, Garrido-Laguna, Ignacio, Naing, Aung, Fu, Siqing, Falchook, Gerald S., Piha-Paul, Sarina A., Wheler, Jennifer J., Hong, David S., Tsimberidou, Apostolia M., Subbiah, Vivek, Zinner, Ralph G., Kaseb, Ahmed O., Patel, Shreyaskumar, Fanale, Michelle A., Velez-Bravo, Vivianne M., Meric-Bernstam, Funda, Kurzrock, Razelle, Janku, Filip
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Clinical Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5341894/
https://ncbi.nlm.nih.gov/pubmed/27589687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11750
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki